Eyelash enhancement properties of topical dechloro ethylcloprostenolamide

To assess subjective reports by users of MD Lash Factor(TM) that it improved the appearance of their eyelashes, especially in length.

A randomized, double-blind, clinical trial was performed on 34 healthy volunteers who were randomly assigned to one of three different treatment groups of varying concentrations of the key ingredient (dechloro ethylcloprostenolamide, a novel synthetic topical prostaglandin analogue) and a placebo group.

All treatment groups demonstrated a statistically significant increase in eyelash length after 4 weeks of daily use. Group A: 1.69 mm, Group B: 1.94 mm, Group D: 1.44 mm, and Group C (placebo): 0.63 mm. There were no complications. Fifteen patients reported minimal initial transient irritation.

Subjective reports by users of improved appearance in their eyelashes were confirmed. Use of dechloro ethylcloprostenolamide had minimal side effects.